Abstract 5557: Systematic mapping of drug sensitivity in hematological malignancies identifies vulnerability of chronic lymphocytic leukemia with mutant p53

Autor: Christof von Kalle, Jan Dürig, Katja Zirlik, Martina Seiffert, Tatjana Stolz, Wolfgang Huber, Malgorzata Oles, Mikolaj Slabicki, Peter Dreger, Ingo Ringshausen, Sascha Dietrich, Thorsten Zenz, Hanno Glimm, Martin Sill, Olaf Merkel, Jennifer Hüllein, Marco Herling, Leopold Sellner, Anna Jauch, Carolin Blume, Manfred Hensel, Marina Lukas, Christopher C. Oakes, Anthony D. Ho, Davide Rossi
Rok vydání: 2014
Předmět:
Zdroj: Cancer Research. 74:5557-5557
ISSN: 1538-7445
0008-5472
Popis: Introduction: The impact of mutations and pathway deregulation for drug sensitivity is only partly understood. Here we systematically investigated heterogeneity of drug response and genetic lesions in leukemia and lymphoma using primary tumor cells in order to identify pathway dependencies which can be exploited by rational treatment approaches. Methods: Primary leukemia / lymphoma cells obtained from peripheral blood were characterized with an ex vivo high-throughput drug screening platform in two steps: In an initial screen 2221 different compounds were tested for cytotoxicity on a limited cohort (n=20). 67 promising compounds targeting different pathways were selected for further validation on a larger cohort (n=111; 97 chronic lymphocytic leukemia (CLL), 5 T-prolymphocytic leukemia (T-PLL), 6 non-CLL B-Non-Hodgkin-Lymphoma (B-NHL), mononuclear cells of 3 healthy donors). Heat inactivated human serum was supplemented to mimic micro-environmental conditions. Cell viability was assessed by quantification of ATP (CellTiterGlo®) 48 and 72 hours after drug application. To understand heterogeneous pathway dependencies, drug sensitivity was regressed on genetic profiles. Genetic characterization was performed by FISH, targeted sequencing of recurrent aberrations (BRAF, MYD88, NOTCH1, SF3B1, TP53) as well as whole exome sequencing. Results: We initially focused on the impact of compounds interfering with or dependent on the p53 pathway. Nutlin-3 and fludarabine induced cell death more efficiently in cells with wild-type (n=80) than in CLL with mutated p53 (n=17; Nutlin-3 10µM: 51±18 vs 80±18; fludarabine 10µM: 40±36 vs 67±23 [% viability of untreated control], both p Citation Format: Leopold Sellner, Malgorzata Oles, Mikolaj Slabicki, Carolin Blume, Jennifer Hüllein, Tatjana Stolz, Marina Lukas, Martin Sill, Christopher C. Oakes, Sascha Dietrich, Olaf Merkel, Anna Jauch, Manfred Hensel, Davide Rossi, Katja Zirlik, Jan Dürig, Ingo Ringshausen, Marco Herling, Martina Seiffert, Peter Dreger, Christof von Kalle, Anthony D. Ho, Hanno Glimm, Wolfgang Huber, Thorsten Zenz. Systematic mapping of drug sensitivity in hematological malignancies identifies vulnerability of chronic lymphocytic leukemia with mutant p53. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 5557. doi:10.1158/1538-7445.AM2014-5557
Databáze: OpenAIRE
Externí odkaz: